Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Appoints David Topper as Chief Financial Officer

Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.
April 05, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
March 28, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
March 11, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.
March 10, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
March 09, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
March 05, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
March 04, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Arcutis today announced the closing of its previously announced underwritten public offering.
March 04, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.
February 29, 2024 17:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...